Back to top
more

DiaSorin (DSRLF)

(Delayed Data from OTC)

$107.40 USD

107.40
NA

0.00 (0.00%)

Updated Apr 24, 2024 03:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for DSRLF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for DiaSorin SpA falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents -99,999 435 477 388 226
Receivables NA 232 257 189 148
Notes Receivable NA 0 0 0 0
Inventories NA 323 353 218 192
Other Current Assets NA 94 47 19 28
Total Current Assets NA 1,084 1,134 816 594
Net Property & Equipment NA 283 327 160 144
Investments & Advances NA 34 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 36 45 38 35
Intangibles NA 2,102 2,299 408 415
Deposits & Other Assets NA 52 5 3 3
Total Assets NA 3,591 3,823 1,424 1,191
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable NA 0 0 0 0
Accounts Payable NA 110 100 75 62
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 15 7 34 12
Other Current Liabilities NA 235 121 74 63
Total Current Liabilities NA 360 124 183 137
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 242 219 12 8
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 1,388 1,632 137 96
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,990 353 331 241
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 59 66 64 63
Capital Surplus NA 19 21 21 20
Retained Earnings NA 1,553 1,290 835 750
Other Equity NA 266 383 298 209
Treasury Stock NA 296 142 125 92
Total Shareholder's Equity NA 1,601 1,618 1,092 950
Total Liabilities & Shareholder's Equity NA 3,591 3,823 1,424 1,191
Total Common Equity 0 1,601 1,618 1,092 950
Shares Outstanding NA 54.70 54.70 55.90 55.90
Book Value Per Share 0.00 29.27 29.59 19.54 17.00

Fiscal Year End for DiaSorin SpA falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 -99,999 -99,999 341 -99,999
Receivables NA NA NA 203 NA
Notes Receivable NA NA NA NA NA
Inventories NA NA NA 352 NA
Other Current Assets NA NA NA 100 NA
Total Current Assets NA NA NA 995 NA
Net Property & Equipment NA NA NA 286 NA
Investments & Advances NA NA NA 27 NA
Other Non-Current Assets NA NA NA NA NA
Deferred Charges NA NA NA 38 NA
Intangibles NA NA NA 2,133 NA
Deposits & Other Assets NA NA NA 15 NA
Total Assets NA NA NA 3,494 NA
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA NA NA NA NA
Accounts Payable NA NA NA 116 NA
Current Portion Long-Term Debt NA NA NA NA NA
Current Portion Capital Leases NA NA NA NA NA
Accrued Expenses NA NA NA NA NA
Income Taxes Payable NA NA NA 23 NA
Other Current Liabilities NA NA NA 169 NA
Total Current Liabilities NA NA NA 308 NA
Mortgages NA NA NA NA NA
Deferred Taxes/Income NA NA NA 241 NA
Convertible Debt NA NA NA NA NA
Long-Term Debt NA NA NA NA NA
Non-Current Capital Leases NA NA NA NA NA
Other Non-Current Liabilities NA NA 1,314 NA
Minority Interest (Liabilities) NA NA NA NA NA
Total Liabilities NA NA NA 1,863 NA
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA NA NA NA NA
Common Stock (Par) NA NA NA 61 NA
Capital Surplus NA NA NA 20 NA
Retained Earnings NA NA NA 1,772 NA
Other Equity NA NA NA 108 NA
Treasury Stock NA NA NA 330 NA
Total Shareholder's Equity NA NA NA 1,631 NA
Total Liabilities & Shareholder's Equity NA NA NA 3,494 NA
Total Common Equity 0 0 0 101,630 0
Shares Outstanding NA NA NA NA 54.70
Book Value Per Share 0.00 0.00 0.00 -1.02 0.00